VIDEO: New Skyrizi, Rinvoq data will help ‘shape our clinical practice’ in IBD management

In a Healio video exclusive, Remo Panaccione, MD, noted the cumulative benefit of Skyrizi and Rinvoq for the induction and maintenance treatment of patients with inflammatory bowel disease.According to phase 3 results from the ADVANCE and MOTIVATE studies presented at the European Crohn’s and Colitis Organization, Skyrizi (risankizumab, AbbVie) induced ‘rapid response and remission’ via IV induction at 12 weeks with maintained endoscopic endpoints through 52 weeks of the FORTIFY maintenance trial.“This is really interesting because it suggests that you have these rapidRead More

Generated by Feedzy